BRIEF-Exelixis and Ipsen announce Phase 3 trial results of CABOMETYX
June 06, 2016 at 02:31 AM EDT
* Announced on Sunday Phase 3 trial results of CABOMETYX (cabozantinib) tablets demonstrating significant overall survival benefit for previously treated patients with advanced renal cell carcinoma presented at ASCO Source text for Eikon: Further company coverage: (Gdynia Newsroom)